Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Letermovir Action Pathway
Homo sapiens
Drug Action Pathway
Letermovir is an antiviral medication that treats cytomegalovirus (CMV) infections and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant.It was approved by the FDA on November 8, 2017 and is the first of the DNA terminase complex inhibitors for CMV.
Cytomegalovirus requires a DNA terminase complex for processing of viral DNA. This complex consists of multiple subunits (pUL51, pUL56, and pUL89). Viral DNA is produced in a single repeating strand which is cut by the DNA terminase complex into individual genomes which can then be packaged into the mature viral particles. Letemovir inhibits the DNA terminase complex, preventing the viral DNA from cutting the DNA and packaging it inside the viral capsid. Thie produces immature, non-infective viruses.
References
Letermovir Pathway References
Crough T, Khanna R: Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev. 2009 Jan;22(1):76-98, Table of Contents. doi: 10.1128/CMR.00034-08.
Pubmed: 19136435
Kropeit D, Scheuenpflug J, Erb-Zohar K, Halabi A, Stobernack HP, Hulskotte EGJ, van Schanke A, Zimmermann H, Rubsamen-Schaeff H: Pharmacokinetics and safety of letermovir, a novel anti-human cytomegalovirus drug, in patients with renal impairment. Br J Clin Pharmacol. 2017 Sep;83(9):1944-1953. doi: 10.1111/bcp.13292. Epub 2017 May 5.
Pubmed: 28345163
Goldner T, Hewlett G, Ettischer N, Ruebsamen-Schaeff H, Zimmermann H, Lischka P: The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol. 2011 Oct;85(20):10884-93. doi: 10.1128/JVI.05265-11. Epub 2011 Jul 13.
Pubmed: 21752907
Chou S: A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. Antiviral Res. 2017 Dec;148:1-4. doi: 10.1016/j.antiviral.2017.10.019. Epub 2017 Oct 28.
Pubmed: 29107686
Neuber S, Wagner K, Goldner T, Lischka P, Steinbrueck L, Messerle M, Borst EM: Mutual Interplay between the Human Cytomegalovirus Terminase Subunits pUL51, pUL56, and pUL89 Promotes Terminase Complex Formation. J Virol. 2017 May 26;91(12):e02384-16. doi: 10.1128/JVI.02384-16. Print 2017 Jun 15.
Pubmed: 28356534
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M: DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037.
Pubmed: 29126136
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Downloads
Settings